[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Renin-Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

April 2024 | 113 pages | ID: G0908927DE5BEN
APO Research

US$ 3,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.

According to APO Research, The global Renin-Inhibitors market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Global Renin-Inhibitors main player is Noden Pharma, etc. Noden Pharma is dominating the market. USA is the largest market, with a share nearly 45%.

This report presents an overview of global market for Renin-Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Renin-Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for Renin-Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Renin-Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Renin-Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Renin-Inhibitors sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Novartis and Noden Pharma etc.

Renin-Inhibitors segment by Company
  • Novartis
  • Noden Pharma
Renin-Inhibitors segment by Type
  • 150mg/Tablet
  • 300mg/Tablet
Renin-Inhibitors segment by Application
  • Age below 45
  • Age 45-55
  • Age 55-65
  • Age above 65
Renin-Inhibitors segment by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • China Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Renin-Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Renin-Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Renin-Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Renin-Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Renin-Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Renin-Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Renin-Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report
1 MARKET OVERVIEW

1.1 Product Definition
1.2 Global Renin-Inhibitors Market Size, 2019 VS 2023 VS 2030
1.3 Global Renin-Inhibitors Market Size Estimates and Forecasts (2019-2030)
1.4 Global Renin-Inhibitors Sales Estimates and Forecasts (2019-2030)
1.5 Global Renin-Inhibitors Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives

2 GLOBAL RENIN-INHIBITORS MARKET DYNAMICS

2.1 Renin-Inhibitors Industry Trends
2.2 Renin-Inhibitors Industry Drivers
2.3 Renin-Inhibitors Industry Opportunities and Challenges
2.4 Renin-Inhibitors Industry Restraints

3 RENIN-INHIBITORS MARKET BY MANUFACTURERS

3.1 Global Renin-Inhibitors Revenue by Manufacturers (2019-2024)
3.2 Global Renin-Inhibitors Sales by Manufacturers (2019-2024)
3.3 Global Renin-Inhibitors Average Sales Price by Manufacturers (2019-2024)
3.4 Global Renin-Inhibitors Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Renin-Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Renin-Inhibitors Manufacturers, Product Type & Application
3.7 Global Renin-Inhibitors Manufacturers Commercialization Time
3.8 Market Competitive Analysis
  3.8.1 Global Renin-Inhibitors Market CR5 and HHI
  3.8.2 Global Top 5 and 10 Renin-Inhibitors Players Market Share by Revenue in 2023
  3.8.3 2023 Renin-Inhibitors Tier 1, Tier 2, and Tier

4 RENIN-INHIBITORS MARKET BY TYPE

4.1 Renin-Inhibitors Type Introduction
  4.1.1 150mg/Tablet
  4.1.2 300mg/Tablet
4.2 Global Renin-Inhibitors Sales by Type
  4.2.1 Global Renin-Inhibitors Sales by Type (2019 VS 2023 VS 2030)
  4.2.2 Global Renin-Inhibitors Sales by Type (2019-2030)
  4.2.3 Global Renin-Inhibitors Sales Market Share by Type (2019-2030)
4.3 Global Renin-Inhibitors Revenue by Type
  4.3.1 Global Renin-Inhibitors Revenue by Type (2019 VS 2023 VS 2030)
  4.3.2 Global Renin-Inhibitors Revenue by Type (2019-2030)
  4.3.3 Global Renin-Inhibitors Revenue Market Share by Type (2019-2030)

5 RENIN-INHIBITORS MARKET BY APPLICATION

5.1 Renin-Inhibitors Application Introduction
  5.1.1 Age below
  5.1.2 Age 45-55
  5.1.3 Age 55-65
  5.1.4 Age above
5.2 Global Renin-Inhibitors Sales by Application
  5.2.1 Global Renin-Inhibitors Sales by Application (2019 VS 2023 VS 2030)
  5.2.2 Global Renin-Inhibitors Sales by Application (2019-2030)
  5.2.3 Global Renin-Inhibitors Sales Market Share by Application (2019-2030)
5.3 Global Renin-Inhibitors Revenue by Application
  5.3.1 Global Renin-Inhibitors Revenue by Application (2019 VS 2023 VS 2030)
  5.3.2 Global Renin-Inhibitors Revenue by Application (2019-2030)
  5.3.3 Global Renin-Inhibitors Revenue Market Share by Application (2019-2030)

6 GLOBAL RENIN-INHIBITORS SALES BY REGION

6.1 Global Renin-Inhibitors Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Renin-Inhibitors Sales by Region (2019-2030)
  6.2.1 Global Renin-Inhibitors Sales by Region (2019-2024)
  6.2.2 Global Renin-Inhibitors Sales Forecasted by Region (2025-2030)
6.3 North America
  6.3.1 North America Renin-Inhibitors Sales Growth Rate by Country: 2019 VS 2023 VS 2030
  6.3.2 North America Renin-Inhibitors Sales by Country (2019-2030)
  6.3.3 U.S.
  6.3.4 Canada
6.4 Europe
  6.4.1 Europe Renin-Inhibitors Sales Growth Rate by Country: 2019 VS 2023 VS 2030
  6.4.2 Europe Renin-Inhibitors Sales by Country (2019-2030)
  6.4.3 Germany
  6.4.4 France
  6.4.5 U.K.
  6.4.6 Italy
  6.4.7 Netherlands
6.5 Asia Pacific
  6.5.1 Asia Pacific Renin-Inhibitors Sales Growth Rate by Country: 2019 VS 2023 VS 2030
  6.5.2 Asia Pacific Renin-Inhibitors Sales by Country (2019-2030)
  6.5.3 China
  6.5.4 Japan
  6.5.5 South Korea
  6.5.6 Southeast Asia
  6.5.7 India
  6.5.8 Australia
6.6 LAMEA
  6.6.1 LAMEA Renin-Inhibitors Sales Growth Rate by Country: 2019 VS 2023 VS 2030
  6.6.2 LAMEA Renin-Inhibitors Sales by Country (2019-2030)
  6.6.3 Mexico
  6.6.4 Brazil
  6.6.5 Turkey
  6.6.6 GCC Countries

7 GLOBAL RENIN-INHIBITORS REVENUE BY REGION

7.1 Global Renin-Inhibitors Revenue by Region
  7.1.1 Global Renin-Inhibitors Revenue by Region: 2019 VS 2023 VS 2030
  7.1.2 Global Renin-Inhibitors Revenue by Region (2019-2024)
  7.1.3 Global Renin-Inhibitors Revenue by Region (2025-2030)
  7.1.4 Global Renin-Inhibitors Revenue Market Share by Region (2019-2030)
7.2 North America
  7.2.1 North America Renin-Inhibitors Revenue (2019-2030)
  7.2.2 North America Renin-Inhibitors Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
  7.3.1 Europe Renin-Inhibitors Revenue (2019-2030)
  7.3.2 Europe Renin-Inhibitors Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
  7.4.1 Asia-Pacific Renin-Inhibitors Revenue (2019-2030)
  7.4.2 Asia-Pacific Renin-Inhibitors Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
  7.5.1 LAMEA Renin-Inhibitors Revenue (2019-2030)
  7.5.2 LAMEA Renin-Inhibitors Revenue Share by Country: 2019 VS 2023 VS 2030

8 COMPANY PROFILES

8.1 Novartis
  8.1.1 Novartis Comapny Information
  8.1.2 Novartis Business Overview
  8.1.3 Novartis Renin-Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
  8.1.4 Novartis Renin-Inhibitors Product Portfolio
  8.1.5 Novartis Recent Developments
8.2 Noden Pharma
  8.2.1 Noden Pharma Comapny Information
  8.2.2 Noden Pharma Business Overview
  8.2.3 Noden Pharma Renin-Inhibitors Sales, Price, Revenue and Gross Margin (2019-2024)
  8.2.4 Noden Pharma Renin-Inhibitors Product Portfolio
  8.2.5 Noden Pharma Recent Developments

9 VALUE CHAIN AND SALES CHANNELS ANALYSIS

9.1 Renin-Inhibitors Value Chain Analysis
  9.1.1 Renin-Inhibitors Key Raw Materials
  9.1.2 Raw Materials Key Suppliers
  9.1.3 Manufacturing Cost Structure
  9.1.4 Renin-Inhibitors Production Mode & Process
9.2 Renin-Inhibitors Sales Channels Analysis
  9.2.1 Direct Comparison with Distribution Share
  9.2.2 Renin-Inhibitors Distributors
  9.2.3 Renin-Inhibitors Customers

10 CONCLUDING INSIGHTS

11 APPENDIX

11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
  11.5.1 Secondary Sources
  11.5.2 Primary Sources
11.6 Disclaimer


More Publications